Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) biologics has revolutionized the treatment and prognosis of several prevalent retinal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic macular edema, and retinal vein occlusion. Here, VEGFA is linked to Abnormal retinal morphology.